Kyntra Bio

Executive Summary

Kyntra Bio is a clinical-stage biotechnology company developing first-in-class therapies for oncology and anemia. Its lead programs include an oral HIF-PH inhibitor for lower-risk myelodysplastic syndrome (LR-MDS) and a CD46-targeting antibody-drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC). The HIF-PH inhibitor aims to address anemia in LR-MDS, a condition with limited treatment options, by stimulating erythropoiesis through hypoxia-inducible factor stabilization. The CD46-ADC leverages a tumor-specific antigen to deliver a potent cytotoxic payload, potentially offering a new therapeutic avenue for mCRPC patients who progress after standard therapies. Both programs are grounded in strong biology and target high-unmet-need indications, positioning Kyntra as a promising player in precision oncology and hematology. The company's strategy focuses on advancing these candidates through clinical development, with an emphasis on generating proof-of-concept data to support future registration trials. With a lean operation based in Cambridge, MA, Kyntra aims to leverage its scientific expertise and partnerships to maximize the impact of its pipeline.

Upcoming Catalysts (preview)

• Q1 2027Phase 1/2 data for CD46-targeting ADC in mCRPC30% success
• Q2 2027Phase 2 data for oral HIF-PH inhibitor in LR-MDS40% success
• Q4 2026Potential partnership or licensing deal for one of the pipeline programs50% success